Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Brighthouse Financial Inc is an insurance-life business based in the US. Brighthouse Financial shares (BHF) are listed on the NASDAQ and all prices are listed in US Dollars. Brighthouse Financial employs 1,400 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$49.99|
|52-week range||$28.74 - $50.96|
|50-day moving average||$46.73|
|200-day moving average||$46.19|
|Wall St. target price||$52.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-52.47|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||1.83%|
|1 month (2021-09-20)||20.14%|
|3 months (2021-07-20)||19.17%|
|6 months (2021-04-20)||11.36%|
|1 year (2020-10-20)||54.86%|
|2 years (2019-10-18)||35.27%|
|3 years (2018-10-19)||19.08%|
|5 years (2016-10-16)||N/A|
Valuing Brighthouse Financial stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Brighthouse Financial's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Brighthouse Financial's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.2 billion.
The EBITDA is a measure of a Brighthouse Financial's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3 billion|
|Gross profit TTM||$929 million|
|Return on assets TTM||-1.46%|
|Return on equity TTM||-24.63%|
|Market capitalisation||$4.1 billion|
TTM: trailing 12 months
There are currently 2.3 million Brighthouse Financial shares held short by investors – that's known as Brighthouse Financial's "short interest". This figure is 13.6% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting Brighthouse Financial shares can be evaluated.
Brighthouse Financial's "short interest ratio" (SIR) is the quantity of Brighthouse Financial shares currently shorted divided by the average quantity of Brighthouse Financial shares traded daily (recently around 689450.60606061). Brighthouse Financial's SIR currently stands at 3.3. In other words for every 100,000 Brighthouse Financial shares traded daily on the market, roughly 3300 shares are currently held short.
However Brighthouse Financial's short interest can also be evaluated against the total number of Brighthouse Financial shares, or, against the total number of tradable Brighthouse Financial shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Brighthouse Financial's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Brighthouse Financial shares in existence, roughly 30 shares are currently held short) or 0.0276% of the tradable shares (for every 100,000 tradable Brighthouse Financial shares, roughly 28 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Brighthouse Financial.
Find out more about how you can short Brighthouse Financial stock.
We're not expecting Brighthouse Financial to pay a dividend over the next 12 months.
Over the last 12 months, Brighthouse Financial's shares have ranged in value from as little as $28.74 up to $50.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Brighthouse Financial's is 1.5566. This would suggest that Brighthouse Financial's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Brighthouse Financial, Inc. provides annuity and life insurance products in the United States. It operates through three segments: Annuities, Life, and Run-off. The Annuities segment offers variable, fixed, index-linked, and income annuities for contract holders' needs for protected wealth accumulation on a tax-deferred basis, wealth transfer, and income security. The Life segment provides term, universal, whole, and variable life policies for policyholders' needs for financial security and protected wealth transfer. The Run-off segment manages structured settlements, pension risk transfer contracts, certain company-owned life insurance policies, funding agreements, and universal life with secondary guarantees. The company was founded in 2016 and is headquartered in Charlotte, North Carolina.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.